1. Taiwan Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
Sunny Pharmtech Inc.

Sunny Pharmtech Inc.

TTPEX:6676
9.97
TWD
-0.33
(-3.20%)
2.08BMarket Cap
Sunny Pharmtech Inc.
TPEX:6676
(Taipei Exchange)

Recent

price

9.97

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
1.25
1.82
3.19
1.77
2.6
3
2.81
- -
- -
Revenue per Share
-2.63
-1.76
-0.77
-1.28
-1.23
-0.44
-1.05
- -
- -
Basic EPS, GAAP
-5.01
-1.54
-0.72
-1.43
-1.22
-0.75
-0.58
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
7.21
8.11
7.39
7.97
6.85
8.08
7.04
- -
6.01
Book Value per Share
6.45
7.41
6.79
7.42
6.29
7.62
6.62
- -
5.61
Tangible Book Value per Share
114
129
131
136
139
143
149
149
149
Basic Weighted Avg Shares
143
234
420
241
360
429
418
- -
- -
Sales/Revenue/Turnover
-198.99
-91.28
-17.7
-73.03
-52.18
-16.81
-38.99
- -
- -
Operating Margin (%)
79
98
106
105
112
121
123
- -
- -
Depreciation Expense
-300
-226
-102
-175
-170
-63
-156
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-209.8
-96.51
-24.23
-72.53
-47.34
-14.77
-37.32
- -
- -
Profit Margin (%)
266
387
304
306
134
349
200
- -
75
Working Capital
312
332
302
293
360
376
341
- -
329
LT Debt
1,020
1,146
1,044
1,126
969
1,200
1,047
- -
895
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-20.89
-9.29
-16.1
-16.25
-5.84
-13.89
- -
- -
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Jun'24
Dec'24
Jun'25
ST Debt
44
45
109
LT Borrowings
306
297
287
LT Finance Leases
46
44
42
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
149
149
149
Market Capitalization
3,920
3,295
2,076

Working Capital

TWD

•

in mil. unless spec.
Jun'24
Dec'24
Jun'25
Total Current Assets
435
365
322
Cash, Cash Equivalents & STI
224
141
82
Accounts Receivable, Net
78
38
44
Inventories
93
123
140
Total Current Liabilities
134
165
247
Payables & Accruals
- -
- -
- -
ST Debt
44
45
109
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
418
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-1.05
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
Sunny Pharmtech Inc. functions as an integrated specialty pharmaceutical enterprise, concentrating on the global research, development, manufacturing, and commercialization of both active pharmaceutical ingredients and finished drug products. The company specializes in creating complex, high-barrier generic drugs and 505(b)(2) products, alongside providing comprehensive Contract Development and Manufacturing Organization (CDMO) support for a variety of dosage forms. Their product range features items like anesthetic ointments, vitamin B12 injections, nitrofurantoin capsules for anti-infective treatment, and aminocaproic acid formulations for hematological conditions. Recent significant achievements include securing U.S. FDA approvals for a multi-cancer injection (CPA-I), an aminocaproic acid solution (AMA-S), and diazepam injection (DZP-I). Sunny Pharmtech is also actively expanding its international presence through licensing agreements for products such as carboprost tromethamine injection in various markets and advancing pipeline therapies for oncology, ulcerative colitis, and rare cardiovascular diseases via strategic partnerships. Founded in 2014, the company is headquartered in Taoyuan, Taiwan, operating U.S. FDA-inspected facilities to deliver high-quality healthcare solutions worldwide.